Petty Thomas L
University of Colorado Medical Center, Denver, CO, USA.
Int J Chron Obstruct Pulmon Dis. 2006;1(1):3-14. doi: 10.2147/copd.2006.1.1.3.
The evolution of knowledge concerning COPD and its components--emphysema, chronic bronchitis, and asthmatic bronchitis--covers 200 years. The stethoscope and spirometer became important early tools in diagnosis and assessment. Spirometry remains the most effective means of identification and assessment of the course of COPD and responses to therapy, and is grossly underused for this purpose. Knowledge of the pathogenesis, course and prognosis, and new approaches to therapy have dramatically improved our understanding of this important clinical entity. Smoking cessation improves the early course of disease. Long-term oxygen improves the length and quality of life in selected patients with hypoxemia. Surgery benefits a select few. Today, COPD is a steadily growing global healthcare problem, with increasing morbidity and mortality. Early identification and prevention, and treatment of emerging stages of disease through smoking cessation and a growing number of bronchoactive drugs promises to change the outcome.
关于慢性阻塞性肺疾病(COPD)及其组成部分——肺气肿、慢性支气管炎和哮喘性支气管炎——的知识演变跨越了200年。听诊器和肺活量计很早就成为诊断和评估的重要工具。肺活量测定仍然是识别和评估COPD病程及治疗反应的最有效手段,但目前在这方面的应用严重不足。对发病机制、病程和预后的了解以及新的治疗方法极大地增进了我们对这一重要临床实体的认识。戒烟可改善疾病的早期病程。长期吸氧可改善部分低氧血症患者的生命长度和质量。手术仅使少数患者受益。如今,COPD已成为一个在全球范围内不断加剧的医疗保健问题,发病率和死亡率都在上升。早期识别、预防以及通过戒烟和越来越多的支气管活性药物对疾病新发阶段进行治疗有望改变结局。